30 September 2020
A descriptive analysis of Regeneron Pharmaceuticals’ clinical trial has found that its antibody cocktail REGN-COV2 lowered the viral load and the time to symptoms improvement in non-hospitalised Covid-19 patients. The therapy also demonstrated positive trends in decreasing medical visits. Safety analysis revealed that both the 8g and 2.4g doses of the therapy were well-tolerated.
CureVac has started dosing participants in a Phase IIa clinical trial of its Covid-19 vaccine candidate, CVnCoV. Being performed in Peru and Panama, the dose-confirmation study will involve 690 healthy volunteers, who will be given two vaccinations spaced 28 days apart. Initial data from the study are expected in the fourth quarter of this year.
An expanded alliance between Serum Institute of India (SII), Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation will see the production and delivery of an additional 100 million doses of Covid-19 vaccines for India and low and middle-income countries (LMICs). This brings the total number of vaccine doses under the collaboration to up to 200 million.
Moderna has reported data from the second interim analysis of Phase I clinical trial of its Covid-19 vaccine candidate, mRNA-1273, which was found to be generally well-tolerated at 25µg and 100µg dose levels in participants aged 56-70 and above 71 years. Immune responses were found to be dose-dependent, with the 100µg dose demonstrating higher binding and neutralising antibody titres.
World Bank president David Malpass has said that the bank is seeking board approval for a $12bn Covid-19 vaccine financing plan to ensure enough vaccine doses are available for poor and developing countries. In an exclusive interview with Reuters, Malpass added that the plan is to help these countries obtain and distribute vaccines early to healthcare and other essential workers, as well as boost manufacturing worldwide.
The Russian Direct Investment Fund (RDIF) has partnered with Trinity Pharmaceuticals to supply 25 million doses of the Sputnik V vaccine to Nepal. The deal is expected to help vaccinate 90% of population in Nepal and provide a Covid-19 vaccine to the country’s clinics. More than 50 Asia, Middle East, Latin America, Europe and CIS countries have applied for the Sputnik V vaccine, noted the RDIF.
China’s Shenzhen Kangtai Biological Products has received approval to conduct a clinical trial of its Covid-19 inactivated vaccine candidate, which was able to elicit antibodies when evaluated in mice and monkeys. The company has also completed a manufacturing facility for the vaccine candidate, pending tests and regulatory certification.